🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

277 results for “combination” Clear

  1. PEMBROLIZUMAB, PEMETREXED DISODIUM, CISPLATIN, PEMETREXED DISODIUM, Relatlimab + Nivolumab Fixed Dose Combination (FDC), CARBOPLATIN

    Bristol-Myers Squibb Australia Pty Ltd

    Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Lenalidomide with a Non-Randomized, Single Arm US Extension of Mosunetuzumab in Combination with Lenalidomide in Patients with Follicular Lymphoma After at Least One Line of Systemic Therapy

    Hoffmann-La Roche

    Relapsed/refractory follicular lymphoma

    phase 3 other active

    1 trial

  3. Placebo in combination with Cytarabine Injection

    Moleculin Biotech

    Acute Myeloid Leukaemia (AML)

    phase 3 small molecule active

    1 trial

  4. Placebo matching Obicetrapib 10 mg tablets, Obicetrapib, Placebo matching Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC) tablets, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)

    Lacuna Pharma Pty Ltd

    Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)

    phase 3 small molecule active

    1 trial

  5. Placebo with a matching appearance to 100 mg niraparib capsules, filled with an excipient blend for clinical development., NIRAPARIB TOSILATE MONOHYDRATE

    TESARO Bio Netherlands B.V.

    Homologous recombination deficiency advanced ovarian cancer

    phase 3 small molecule active

    1 trial

  6. Placebo, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)

    Lacuna Pharma Pty Ltd

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  7. RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)

    RedHill Biopharma

    Crohn Disease

    phase 3 small molecule completed

    1 trial

  8. RITUXIMAB, METHOTREXATE, MYCOPHENOLATE MOFETIL, RoActemra 162 mg solution for injection in pre-filled pen., AZATHIOPRINE, XELJANZ 5 mg film-coated tablets

    Pari Pharma GmbH

    Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.

    phase 3 small molecule active

    1 trial

  9. Ramelteon and Placebo (9 possible combinations total)

    Takeda

    Chronic Insomnia

    phase 3 small molecule completed

    1 trial

  10. Selinexor (combination therapy)

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  11. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  12. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.

    phase 3 small molecule active

    1 trial

  13. Tezspire 210 mg solution for injection in pre-filled syringe, Tezepelumab-placebo

    AstraZeneca AB

    Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus

    phase 3 small molecule active

    1 trial

  14. VX-445/VX-661/VX-770 fixed-dose combination granules, VX-445/VX-661/VX-770 fixed-dose combination granules, Kalydeco 75 mg granules in sachet, Kalydeco 75 mg film-coated tablets, VX-770 75mg, VX-770 granules, Kaftrio 37.5 mg/25 mg/50 mg film-coated tablets, Kaftrio 75 mg/50 mg/100 mg film-coated tablets, Kalydeco 150 mg film-coated tablets

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  15. VX-445/VX-661/VX-770 fixed-dose combination granules, VX-770 75mg, VX-770 granules, Kaftrio 75 mg/50 mg/100 mg granules in sachet, Kalydeco 50 mg granules in sachet, VX-445/VX-661/VX-770 fixed-dose combination granules, Kaftrio 60 mg/40 mg/80 mg granules in sachet, VX-770 50mg, Kalydeco 59.5 mg granules in sachet, Kalydeco 25 mg granules in sachet, Kalydeco 75 mg granules in sachet, VX-445/VX-661/VX-770 granules, VX-445/VX-661/VX-770 granules, Ivacaftor 25 mg granules

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  16. VX-661 Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    2 trials

  17. VX-770 granules, VX-445/VX-661/VX-770 fixed-dose combination granules, VX-445/VX-661/VX-770 granules, Kalydeco 25 mg granules in sachet, VX-445/VX-661/VX-770 granules, Kalydeco 50 mg granules in sachet

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule active

    1 trial

  18. Venetoclax in combination with fludarabine and melphalan

    The First People's Hospital of Lianyungang

    Venentoclax

    phase 3 small molecule active

    1 trial

  19. casirivimab+imdevimab combination therapy

    Regeneron UK Limited

    COVID-19

    phase 3 small molecule terminated

    1 trial

  20. doxorubicin in combination with palifosfamide-tris

    Alaunos Therapeutics

    Soft Tissue Sarcoma

    phase 3 small molecule completed

    1 trial

  21. fixed dose combination of telmisartan+amlodipine

    Boehringer Ingelheim

    Hypertension

    phase 3 small molecule completed

    1 trial

  22. olmesartan alone or in combination with hydrochlorothiazide

    Pfizer

    Essential Hypertension

    phase 3 small molecule completed

    1 trial

  23. rhTPO in combination with Rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Purpura

    phase 3 small molecule completed

    1 trial

  24. telmisartan/amlodipine 40/5 mg fixed combination

    Boehringer Ingelheim

    Hypertension

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources